You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Response to: Should we give long-term macrolide therapy for COPD?
  1. Richard K Albert
  1. Correspondence to Dr Richard K Albert, Department of Medicine, Denver Health, 777 Bannock MC 4000, Denver, CO 80204-4507, USA; ralbert{at}dhha.org

https://doi.org/10.1136/thoraxjnl-2013-204089

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The letter submitted by Crosbie and Woodhead1 pertaining to our study of azithromycin for prevention of acute chronic obstructive pulmonary disease (COPD) exacerbations2 contains a number of errors and misconceptions.

    First, Crosbie and Woodhead stated that our study was not double-blind. The complete protocol (published as an on-line supplement to the manuscript) indicated that ‘This is a prospective, randomised, double-blind, placebo-controlled trial…’.1

    Second, while Crosbie and Woodhead correctly note that …

    View Full Text

    Footnotes

    • Funding This work was supported by National Heart Lung and Blood Institute grant number NHLBI 1 U10 HL074409-01. Supported conduct of study.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles